Trial Profile
Phase II Clinical Study of CM082 Combined With JS001 in the Treatment of Advanced Mucinous Melanoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Toripalimab (Primary) ; Vorolanib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Sponsors AnewPharma
- 31 May 2020 Results (data cut-off November 28, 2019; n= 29), investigatinf the safety and efficacy of CM082 in combination with JS001 in patients (pts) with advanced mucosal melanoma, presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 02 Jul 2019 Planned number of patients changed from 20 to 40.
- 19 Feb 2019 Status changed from not yet recruiting to recruiting.